Aim. To evaluate the effectiveness of magnesium rotate in the patients with cardiac arrhythmias, arterial hypertension (AH), and idiopathic mitral valve prolapse (MVP) Material and methods. The complex examination. dynamic follow-up, and placebo-controlled differentiated treatment were performed in 84 patients with idiopathic MVP. All participants underwent echocardiography, 24-hour blood pressure monitoring (BPM) and electrocardiography (ECG) monitoring, office BP measurement, spectral analysis of heart rate variability (HRV), and physical stress test The main group (MG, n=43) received magnesium orotate (3000 mg/d) for 6 months, the comparison group (CG; n=41) received placebo. Results. According to the 24-hour ECG monitoring data, the treatment was associated with disappearance of high-grade arrhythmias and a 40% reduction in supraventricular (paroxysmal and non-paroxysmal) tachycardia incidence The number of ventricular extrasystoles was reduced in 26%, and they disappeared in 54%. In 8%, polytopic ventricular extrasystoles were substituted by occasional monotopic extrasystoles These changes were not observed in the CG patients The percentage of Stage I AH patients decreased from 38% to 8% in the MG, and from 30% to 20% in the CG Conclusion. In MVP patients,. magnesium orotate treatment improved electro-physiological heart parameters, with reduced supraventricular and ventricular extrasystole incidence and improved circadian BP profile.
